Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome
Key facts
- Who runs it
- Wuhan Children's Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 91 people enrolled
- Started
- 1 Jan 2021
- Ended
- 31 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Rituximab
- Targeted Nursing Care
- Baseline Glucocorticoid Therapy
- Tacrolimus
- Record updated
- 1 October 2025
Who can take part
- Age
- 6 years to 15 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Diagnosis of primary pediatric nephrotic syndrome, specifically steroid-dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS), as defined by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. (SDNS is defined as relapse occurring during tapering of glucocorticoids or within 14 days of discontinuation; FRNS is defined as ≥2 relapses within 6 months of initial response or ≥4 relapses in any 12-month period)
- Age between 6 and 15 years
- Normal intellectual development and the ability to understand and communicate
- Informed consent obtained from the guardians and assent from children capable of understanding
Who cannot take part
- Prior treatment with rituximab or tacrolimus
- Steroid-resistant nephrotic syndrome (SRNS)
- Severe renal insufficiency (according to KDIGO criteria or other relevant standards)
- Cognitive or mental disorders
- Worsening condition upon admission necessitating intensive care
- Co-existing significant kidney, urinary system diseases (other than NS), or severe active urinary tract infection
- Significant liver function impairment
- Known hypersensitivity to rituximab or tacrolimus
- Parents unable to provide long-term care or unwilling to participate
- Interruption of hospitalization for any reason
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study investigated the combined impact of rituximab and targeted nursing care versus tacrolimus and targeted nursing care on efficacy, quality of life, adverse reactions, and recurrence rate in children with challenging (steroid-dependent or frequently relapsing) nephrotic syndrome. Ninety-one pediatric patients were randomized to either receive rituximab plus targeted nursing or tacrolimus plus targeted nursing, and outcomes were assessed over a 6-month period.
The 2 groups in the trial
- Rituximab with Targeted Nursing CareTreatment being tested
Patients received intravenous rituximab in conjunction with baseline glucocorticoid therapy and a standardized targeted nursing care program
Treatment: Rituximab, Targeted Nursing Care, and Baseline Glucocorticoid Therapy
- Tacrolimus with Targeted Nursing CareExisting treatment, for comparison
Patients received oral tacrolimus capsules in conjunction with baseline glucocorticoid therapy and a standardized targeted nursing care program identical to the study group.
Treatment: Targeted Nursing Care, Baseline Glucocorticoid Therapy, and Tacrolimus
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Rituximab in Reducing Relapses in Children With Steroid-Sensitive Nephrotic Syndrome: An Open-label, Multi-center Clinical Study.
- Publications
- Record updated
- 1 October 2025